oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This study will be a Phase 1, multi-center, open-label, dose escalation followed by the
recommended phase 2 dose (RP2D) expansion study to characterize safety, tolerability,
biodistribution, virus shedding and preliminary efficacy of intratumoral injection of BS006
in patients with advanced solid tumors.